Lead Story
Timor-Leste's WHO validation makes Southeast Asia the first WHO region to eliminate trachoma
The World Health Organization announced on September 3, 2026, that it had validated Timor-Leste as having eliminated trachoma as a public health problem, making it the last country in the WHO South-East Asia Region to reach the milestone and completing the region's elimination of the disease, the leading infectious cause of blindness worldwide. WHO formally recognized the region-wide achievement at its 79th Regional Committee session on September 8, alongside Thailand's validated elimination of rubella. Regional health officials credited decades of the WHO-backed SAFE strategy -- surgery, antibiotics, facial cleanliness and environmental improvement -- for protecting millions from the blinding disease, with coverage of the milestone continuing through mid-September as a landmark for the region's health systems.
Read more →Lead Story
Timor-Leste's WHO validation makes Southeast Asia the first WHO region to eliminate trachoma
The World Health Organization announced on September 3, 2026, that it had validated Timor-Leste as having eliminated trachoma as a public health problem, making it the last country in the WHO South-East Asia Region to reach the milestone and completing the region's elimination of the disease, the leading infectious cause of blindness worldwide. WHO formally recognized the region-wide achievement at its 79th Regional Committee session on September 8, alongside Thailand's validated elimination of rubella. Regional health officials credited decades of the WHO-backed SAFE strategy -- surgery, antibiotics, facial cleanliness and environmental improvement -- for protecting millions from the blinding disease, with coverage of the milestone continuing through mid-September as a landmark for the region's health systems.
FDA approves first RAS-targeted drug for metastatic pancreatic cancer, nearly doubling survival
The US Food and Drug Administration approved daraxonrasib, sold as Rasonque, on August 26, 2026, as the first broad RAS-targeted therapy for adults with previously treated metastatic pancreatic adenocarcinoma, one of the deadliest and hardest-to-treat cancers. In the late-stage RASolute 302 trial of 500 patients, those who took the daily pill from Revolution Medicines lived a median of about 13.2 months, nearly double the roughly 6.7 months seen with standard chemotherapy. Oncologists described the approval as a rare and significant advance for a cancer whose five-year survival rate has long remained in the single digits, offering new hope for patients who progress after initial treatment.
Read more →FDA approves first RAS-targeted drug for metastatic pancreatic cancer, nearly doubling survival
The US Food and Drug Administration approved daraxonrasib, sold as Rasonque, on August 26, 2026, as the first broad RAS-targeted therapy for adults with previously treated metastatic pancreatic adenocarcinoma, one of the deadliest and hardest-to-treat cancers. In the late-stage RASolute 302 trial of 500 patients, those who took the daily pill from Revolution Medicines lived a median of about 13.2 months, nearly double the roughly 6.7 months seen with standard chemotherapy. Oncologists described the approval as a rare and significant advance for a cancer whose five-year survival rate has long remained in the single digits, offering new hope for patients who progress after initial treatment.
US clean power capacity hits record high, now enough to power 83 million homes
The American Clean Power Association's Q2 2026 market report, released in early September, found the US added 17,058 megawatts of new utility-scale solar, battery storage and land-based wind capacity in the second quarter -- a 45% jump over the same period in 2025 and the strongest second quarter and first half of any year on record. Cumulative US clean power capacity reached 387,606 megawatts, enough to supply electricity to roughly 83.2 million American homes, with utility-scale solar accounting for the largest share of new additions. The milestone landed during National Clean Energy Week, running September 14-18, 2026, as developers pointed to falling technology costs and long project pipelines sustaining the buildout.
Read more →US clean power capacity hits record high, now enough to power 83 million homes
The American Clean Power Association's Q2 2026 market report, released in early September, found the US added 17,058 megawatts of new utility-scale solar, battery storage and land-based wind capacity in the second quarter -- a 45% jump over the same period in 2025 and the strongest second quarter and first half of any year on record. Cumulative US clean power capacity reached 387,606 megawatts, enough to supply electricity to roughly 83.2 million American homes, with utility-scale solar accounting for the largest share of new additions. The milestone landed during National Clean Energy Week, running September 14-18, 2026, as developers pointed to falling technology costs and long project pipelines sustaining the buildout.
Fin whales stage dramatic comeback in Antarctic waters after near-extinction from whaling
Researchers reported this week, in an Inside Climate News piece published September 17, 2026, that fin whales have rebounded strongly in the Southern Ocean near Antarctica's Elephant Island, with observers recording groups of 50 to 70 animals feeding together and subsequent surveys finding aggregations of up to 150 whales -- densities resembling the 'from horizon to horizon' scenes described by early 20th-century Antarctic explorers before industrial whaling decimated the population. The recovery follows the 1986 global ban on commercial whaling, which allowed the species, once hunted to the brink, decades to slowly rebuild its numbers. Scientists cautioned that expanding commercial krill fishing in the same waters could threaten to undercut the comeback if left unmanaged.
Read more →Fin whales stage dramatic comeback in Antarctic waters after near-extinction from whaling
Researchers reported this week, in an Inside Climate News piece published September 17, 2026, that fin whales have rebounded strongly in the Southern Ocean near Antarctica's Elephant Island, with observers recording groups of 50 to 70 animals feeding together and subsequent surveys finding aggregations of up to 150 whales -- densities resembling the 'from horizon to horizon' scenes described by early 20th-century Antarctic explorers before industrial whaling decimated the population. The recovery follows the 1986 global ban on commercial whaling, which allowed the species, once hunted to the brink, decades to slowly rebuild its numbers. Scientists cautioned that expanding commercial krill fishing in the same waters could threaten to undercut the comeback if left unmanaged.
Malaria vaccine rollout drives sharp case declines across Africa
A Nature Africa report this month found that malaria vaccine distribution reached 28.3 million doses in 2025, a 169% increase over the prior year, with 25 African countries now implementing the vaccines as of April 2026, including nine of the ten highest-burden countries. The real-world impact is showing clearly in early adopters: Cameroon documented a 17% reduction in laboratory-confirmed malaria cases between 2024 and 2025, while Burkina Faso, which introduced the vaccine in February 2024, saw total cases fall from 10.8 million to 7.3 million, a 32% drop, including a 38% decline among children under five. Gavi has forecast that fully immunizing roughly 50 million children between 2026 and 2030 could save more than 170,000 lives.
Read more →Malaria vaccine rollout drives sharp case declines across Africa
A Nature Africa report this month found that malaria vaccine distribution reached 28.3 million doses in 2025, a 169% increase over the prior year, with 25 African countries now implementing the vaccines as of April 2026, including nine of the ten highest-burden countries. The real-world impact is showing clearly in early adopters: Cameroon documented a 17% reduction in laboratory-confirmed malaria cases between 2024 and 2025, while Burkina Faso, which introduced the vaccine in February 2024, saw total cases fall from 10.8 million to 7.3 million, a 32% drop, including a 38% decline among children under five. Gavi has forecast that fully immunizing roughly 50 million children between 2026 and 2030 could save more than 170,000 lives.